News for Siegfried Holding AG (SGFEF)

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular ede

Core EBITDA Margin: Exceeded 22%, reaching 22.1%.Core Net Profit: Increased by 24% to CHF 158.9 million.Revenue Growth: Underlying business grew by 8% to 9% in

**media[542970]**

Siegfried AG / Key word(s): Expansion DINAMIQS opens new lab in Zurich 12.11.2024 / 06:30 CET/CEST Media Release Zofingen, ...

Release Date: August 22, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Siegfried Hold

Driven by Demand for Outsourced Biologics Production, the Biopharmaceutical Contract Manufacturing Organization (CMO) Market Surges with Expansion in...

The global pharmaceutical CDMO market size is anticipated to grow from USD 150 billion to USD 295.07 billion in 10 years. The market will experience rapid...

Visiongain has published a new report entitled Pharmaceutical Contract Manufacturing Market Report 2024-2034: Forecasts by Services (Pharmaceutical...

Advancements and Projections in the CDMO Market: Insights, Trends, Opportunities, and Recent Developments...

The healthcare contract manufacturing market size was valued at USD 192.4 Billion in 2023 and is expected to reach a market size of USD 417.4 Billion by...

CFRA raises Lonza shares target, retains "Buy" rating

Feb 20, 2024 / 01:00PM GMTPeter Stierli - Siegfried Holding AG - Head Corporate Communications Good afternoon. Welcome to the presentation of our full-year resu

Aug 17, 2023 / 08:00AM GMTPeter Stierli - Siegfried Holding AG - Head of Corporate Communications Good morning, and welcome to the presentation of our half year

Aug 18, 2022 / 08:00AM GMTPeter Stierli - Good morning, ladies and gentlemen. Welcome to the presentation of our half year 2022 results. My name is Peter Stier

Feb 23, 2022 / 12:30PM GMTPeter A. Gehler - Siegfried Holding AG - Chief Communications Officer Ladies and gentlemen, I would like to welcome you to the present

Notice of Annual General Meeting Notice is hereby given that the Annual General Meeting of DSV A/S will be held on: ...

/PRNewswire/ -- The "Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2029" & "Pharmaceutical Excipients Global Market - Forecast To 2029"...

Notice is hereby given that the Annual General Meeting of DSV A/S will be held on: Thursday, 16 March 2023, at 14:00 CET, at DSV A/S’ registered office DSV...